Notably, some of these samples had NPM1, DNMT3A, and FLT3-ITD mutations co-occurring, which has a deleterious effect (1); ASXL1, WT1, and FLT3 mutations that carry a poor prognosis (1, 4, 15, 16); BCOR, CBL, IDH1/2, and RAS mutations that confer drug resistance (10, 14, 33); SRSF2, EZH2, and BCOR mutations that are associated with secondary AML (4); and more. This evidence concerns the gene EZH2 and acute myeloid leukemia.